Owing to their enhanced targeting capability and robust photothermal stability, PSMA-OSP12 NPs enabled effective photothermal ablation of PSMA-positive prostate tumors with minimal systemic toxicity in vivo. Here, FOLH1 is linked to prostate neoplasm.